BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti December Small Cap Conference, taking place virtually from December 6-7, 2023. Details are as follows:
Sidoti December Small Cap Conference
Format: Company Presentation
Date and Time: Wednesday, December 6, 2023, from 12:15 pm - 12:45 pm EST
Location: Virtual
A live webcast of the presentation can be accessed from the Investors section of the Athira website or by clicking here.. An archived replay will be available for at least 30 days following the event.
Athira Pharma will also host virtual one-on-one meetings with investors on Wednesday, December 6 and Thursday, December 7. To register for the conference and schedule a one-on-one meeting, please visit https://sidoti.com/events.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological disease by advancing its pipeline of therapeutic candidates targeting the HGF neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic lateral sclerosis. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on X, formerly known as Twitter, and Instagram.
Investor & Media Contact:
Julie Rathbun
Athira Pharma
This email address is being protected from spambots. You need JavaScript enabled to view it.
206-769-9219
Last Trade: | US$0.58 |
Daily Change: | 0.03 5.11 |
Daily Volume: | 244,007 |
Market Cap: | US$22.270M |
November 07, 2024 October 22, 2024 September 17, 2024 September 03, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB